Skip to main content

REVIEW article

Front. Med.
Sec. Gene and Cell Therapy
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1447147
This article is part of the Research Topic Emerging Evidence of Cell-Based Therapies for Non-malignant and Non-genetic Diseases View all 4 articles

CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases

Provisionally accepted
Jovana Vukovic Jovana Vukovic 1*Dzihan Abazovic Dzihan Abazovic 1*Dusan Vucetic Dusan Vucetic 2Sanja Medenica Sanja Medenica 3,4
  • 1 University of Belgrade, Faculty of Medicine, Belgrade, Serbia
  • 2 Institute for Transfusiology and hemobiology, Military Medical Academy, Belgrade, Serbia
  • 3 Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
  • 4 Department of Endocrinology, Internal Medicine Clinic, Clinical Center of Montenegro, Podgorica, Montenegro, Podgorica, Montenegro

The final, formatted version of the article will be published soon.

    Abstracts CAR-T therapy has demonstrated great success in treating hematological malignancies, which has led to further research into its potential in treating other diseases. Autoimmune diseases have great potential to be treated with this therapy due to the possibility of specific targeting of pathological immune cells and cells that produce autoantibodies, which could lead to permanent healing and restoration of immunological tolerance. Several approaches are currently under investigation, including targeting and depleting B cells via CD19 in the early stages of the disease, simultaneously targeting B cells and memory plasma cells in later stages and refractory states, as well as targeting specific autoantigens through the chimeric autoantibody receptor (CAAR). Additionally, CAR-engineered T regulatory cells can be modified to specifically target the autoimmune niche and modulate the pathological immune response. The encouraging results from preclinical studies have led to the first successful use of CAR-T therapy in humans to treat autoimmunity. This paved the way for further clinical studies, aiming to evaluate the long-term safety and efficacy of these therapies, potentially revolutionising clinical use.

    Keywords: Autoimmunity, car-t, CAAR-T, CAR-Treg, Immunotherapy, cell therapy, Regenerative Medicine

    Received: 11 Jun 2024; Accepted: 30 Sep 2024.

    Copyright: © 2024 Vukovic, Abazovic, Vucetic and Medenica. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jovana Vukovic, University of Belgrade, Faculty of Medicine, Belgrade, Serbia
    Dzihan Abazovic, University of Belgrade, Faculty of Medicine, Belgrade, Serbia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.